Matrix metalloproteinases contribute to insulin insufficiency in zucker diabetic fatty rats

Diabetes

Volumn 54, Issue 9, 2005, Pages 2612-2619

  Zhou, Yun Ping ^a,c   Madjidi, Azadeh ^a   Wilson, Maria E ^a   Nothhelfer, David A ^a   Johnson, John H ^b   Palma, John F ^a,d   Schweitzer, Anthony ^a   Burant, Charles ^b,e   Blume, John E ^a,d   Johnson, Jeffrey D ^a  

^a Metabolex   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Thermo Fisher Scientific   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4' BROMOBIPHENYL 4 SULFONYLAMINO) 3 METHYLBUTYRIC ACID; GELATINASE A; INSULIN; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; OLIGONUCLEOTIDE; PD166793; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; GENE EXPRESSION; INSULIN DEFICIENCY; MALE; MOUSE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANIMALS; DIETARY FATS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYDROXAMIC ACIDS; INSULIN; ISLETS OF LANGERHANS; MALE; MATRIX METALLOPROTEINASES; OLIGOPEPTIDES; RATS; RATS, ZUCKER; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 24144443158     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.9.2612     Document Type: Article

References (35)

1. Kahn BB: Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 92:593-596, 1998
2. Cavaghan MK, Erhmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invet 106:329-333, 2000
3. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529, 2001
4. Porte D Jr: Banting Lecture 1990: β-Cells in type II diabetes mellitus. Diabetes 40:166-180, 1990
5. Kahn SE: Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058, 2001
6. Turner RC, Cull CA Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012, 1999
7. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR: β-Cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15:290-296, 1998
8. Milburn JL Jr, Hirose H, Lee YH, Nagasawa Y, Ogawas A, Ohneda M, BeltrandelRio H, Newgard CB, Johnson JH, Unger RH: Pancreatic beta-cells in obesity: evidence for induction of functional, morphological, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 270:1295-1299, 1995
9. Cockburn BN, Ostrega DM, Sturis J, Kubstrup C, Polonsky KS, Bell GI: Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity and the onset of diabetes. Diabetes 46:1434-1439, 1997
10. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:1249-1258, 1985
11. Clark A, Wells CA, Bluey ID, Cruickshank JK, Vanhegan IR, Matthews DR, Copper GJS, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
13. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desai NM, Koberlein B, Wolf B, Barker CF, Naji A, Matschinsky FM, Markmann JF: Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624-632, 2004
14. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS: Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358-364, 1998
15. Bonner-Weir S: Life and death of the pancreatic beta cells. Trends Endocrinol Metab 11:375-378, 2000
16. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE: Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 148:231-241, 2000
17. Zhou YP, Marlen K, Palma JF, Schweitzer A, Reilly L, Gregoire FM, Xu GG, Blume JE, Johnson JD: Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets: a common mechanism for glucotoxicity and lipotoxicity? J Biol Chem 278:51316-51323, 2003
18. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392, 2002
19. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003
20. Liekens S, de Clercq E, Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61:253-270, 2001
21. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, Libert C: Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 7:1202-1208, 2001
22. Luttun A, Dewerchin M, Collen D, Carmeliet P: The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep 2:407-416, 2000
23. Zucker S, Cao J, Chen T: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-6650, 2000
24. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ: Membrane-type I matrix metalloproteinases usurp tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114:33-45, 2003
25. O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H: Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem 43:156-166, 2000
26. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103:2303-2309, 2001
27. Lacy P, Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35-39, 1967
28. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI: Evolution of β-cell dysfunction in male Zucker diabetic fatty rat. Diabetes 44:1447-1157, 1995
29. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE: β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029, 2001
30. Janssen SW, Hermus AR, Lange WP, Krujnenburg Q, van der Laak JA, Sweep CG, Martens GJ, Verhofstad AA: Progressive histopathological changes in pancreatic islets of Zucker diabetic fatty rats. Exp Clin Endocrinol Diabetes 10:273-282, 2001
31. Tomita T, Iwata K: Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Path 10:47-54, 1997
32. Barro C, Zaoui P, Morel F, Benhamou PY: Matrix metalloproteinase expression in rat pancreatic islets Pancreas 17:378-382, 1998
33. Miettinen PJ, Huotari M, Koivisto T, Ustinov J, Palgi J, Rasilainen S, Lehtonen E, Keski-Oja J, Otonkoski T: Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors. Development 127:2617-2627, 2000
34. Miralles F, Battelino T, Czernichow P, Scharfmann R: TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2. J Cell Biol 143:827-836, 1998
35. Lee SR, Tsuji K, Lee SR, Lo EH: Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671-678, 2004